ArticleBMC nephrology2025
Cystatin C as a predictor of renal recovery and in hospital mortality in patients with acute kidney injury and liver cirrhosis.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Renal Biomarkers and Albuminuria Predict Early Adverse Outcomes in Cardiorenal Syndrome Type 2.Medical sciences (Basel, Switzerland) · 2026Observational
- The Role of Biomarkers in Personalized Anesthesia: From Physiological Parameters to Molecular Diagnostics.Biomedicines · 2026Review
- Association between red blood cell distribution width to albumin ratio and prognosis in patients with sepsis-associated acute kidney injury: a retrospective cohort study.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute kidney injury (AKI) is a common and serious complication in patients with liver cirrhosis, with pre-renal AKI and acute tubular necrosis being the most frequent underlying causes. Cystatin C is a non-glycosylated 13 kDa protein that is consistently produced by all nucleated cells and has been suggested as a potential predictor of mortality in this patient population. The role of cystatin C in predicting renal recovery in these patients is not known and this was the aim of our study.
methodsThis was a retrospective single center study that included hospitalized patients with liver cirrhosis who developed or were admitted with AKI and had serum cystatin C in their records from May 2017 to May 2023. The sociodemographic and laboratory data were retrieved from the data system. The in-hospital mortality, length of hospital stay, and renal recovery were recorded. Renal recovery was defined as a reduction in serum creatinine without needing dialysis on discharge.
resultsThis study included 209 patients with AKI and liver cirrhosis. Sixty-five patients (31%) died during hospital admission. The renal recovery was shown in 136 patients (65%). White blood cells, serum albumin, and peak serum cystatin C were the significant predictors for in-hospital mortality (p = 0.021, 0.013, and 0.001, respectively). Hypertension, serum albumin, baseline creatinine and baseline cystatin C were significant predictors of renal recovery in the studied patients (p = 0.017, 0.006, 0.030, and < 0.001, respectively). The cut-off value of baseline serum cystatin C for prediction of renal recovery was 2.62 with moderate sensitivity and specificity.
conclusionIn the current study, baseline serum cystatin C is a predictor of renal recovery in patients with AKI and liver cirrhosis. However, peak serum cystatin C is a predictor of mortality in these patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.